Literature DB >> 20064443

Kickstarting Foxp3 with c-Rel.

Chyi-Song Hsieh1.   

Abstract

In this issue of Immunity, reports by Long et al. (2009) and Ruan et al. (2009) suggest that the transcription factor NF-kappaB-c-Rel is an important molecular mechanism by which T cell receptor-specificity for self-antigens instructs the selection of Foxp3(+) regulatory T cells. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20064443     DOI: 10.1016/j.immuni.2009.11.006

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  5 in total

Review 1.  NF-κB in immunobiology.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

2.  miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Authors:  Yunjie Lu; Keli L Hippen; Amanda L Lemire; Jian Gu; Weizhi Wang; Xuhao Ni; Parvathi Ranganathan; Bruce L Levine; James L Riley; Carl H June; Laurence A Turka; David H Munn; Ramiro Garzon; Ling Lu; Bruce R Blazar
Journal:  Blood       Date:  2016-08-02       Impact factor: 22.113

Review 3.  A key role for NF-κB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions.

Authors:  Alexander Visekruna; Anton Volkov; Ulrich Steinhoff
Journal:  Clin Dev Immunol       Date:  2012-03-06

4.  c-Rel controls multiple discrete steps in the thymic development of Foxp3+ CD4 regulatory T cells.

Authors:  George Grigoriadis; Ajithkumar Vasanthakumar; Ashish Banerjee; Raelene Grumont; Sarah Overall; Paul Gleeson; Frances Shannon; Steve Gerondakis
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

5.  The Treg-specific demethylated region stabilizes Foxp3 expression independently of NF-κB signaling.

Authors:  Lisa Schreiber; Beate Pietzsch; Stefan Floess; Carla Farah; Lothar Jänsch; Ingo Schmitz; Jochen Huehn
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.